MAM
Ormax predicts 60% slot growth for Zee with ‘Hitler Didi’
MUMBAI: Zee TV‘s latest fiction show, Hitler Didi, may have a first-week average TVR of 1.6 at the 8 pm slot.
The predicted opening is a 60 per cent growth on the current rating of 1 TVR for ‘Shobha Somnath Ki‘.
The predictions are according to Ormax Media‘s predictive model based on their awareness tracking tool Showbuzz. The media consulting and research firm said that the actual TVR may vary by up to 15 per cent, depending on the actual content of the programme.
As per Ormax, the show has scored 15 per cent on Unaided Awareness and 84 per cent on Total Awareness on Showbuzz amongst female audiences, in the week before its launch. This is the best performance for a Zee TV fiction show on Showbuzz since the last two years. In November 2009, ‘Yahan Main Ghar-Ghar Kheli‘ had scored 17 per cent and 78 per cent respectively one week before its launch.
Showbuzz tracks awareness of new programmes across six markets. Data over the last two years has been used to create a predictive model for fiction shows. The model predicts the opening week reach of the launches, which can then be used to arrive at indicative TVR, assuming a certain level of content.
The model takes into account the marketing buzz created by the show, the performance of the slot, competitive scenario, overall channel performance, audience flow from one show to the other and the category of the programme.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
